Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185857 | 0.83 | HRH3 (0.53) | ALDH1A1SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL6746536 | 0.83 | HRH3 (0.53) | ALDH1A1SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL27896416 | 0.78 | MEN1 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL27918437 | 0.77 | MC4R (0.53) | ALDH1A1SMN1; SMN2KDM4EHPGDPOLB | |
| SCHEMBL28159525 | 0.77 | GAA (0.57) | ALDH1A1SMN1; SMN2KMT2AHSD17B10MAPT | |
| SCHEMBL3462006 | 0.77 | MC4R (0.53) | ALDH1A1SMN1; SMN2KDM4EHPGDPOLB | |
| SCHEMBL28846715 | 0.77 | GAA (0.57) | ALDH1A1SMN1; SMN2KMT2AHSD17B10MAPT | |
| SCHEMBL9672303 | 0.76 | SIGMAR1 (0.52) | ALDH1A1SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL7241560 | 0.74 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL4947647 | 0.73 | HTT (0.65) | ALDH1A1SMN1; SMN2MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | ALDH1A1 3511/4885SMN1; SMN2 1837/4885MEN1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.